Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Dana-Farber Names Senior VP for Drug Discovery

June 14, 2024

July 2024

Scott Armstrong, MD, PhD, was named senior vice president for drug discovery and chief research strategy officer by the Dana-Farber Cancer Institute in Boston. He is currently chair of the Department of Pediatric Oncology and will remain in this role until it is filled.

In his new role, Dr. Armstrong will lead the Institute’s research strategy, focusing on therapeutic discovery.

A leader in epigenetics research and drug discovery, Dr. Armstrong’s research focuses on small molecules that target chromatin complexes and gene expression in cancer, particularly common subtypes of aggressive acute myelogenous leukemias.

Throughout his career, Dr. Armstrong has also led the Department of Pediatric Oncology and served as president of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital, professor of pediatrics at the Weill Cornell Medical College, and director of the Center for Epigenetics Research at Memorial Sloan Kettering Cancer Center.

He was also elected as a fellow of the American Association for the Advancement of Science and is a member of the National Academy of Medicine.

“Scott Armstrong’s outstanding research has already helped treat patients with cancer,” said Laurie H. Glimcher, MD, president and chief executive officer of Dana-Farber. “He is uniquely well-suited for these new roles at this pivotal time.”

Source: Dana-Farber, March 14, 2024.

 

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals